Cancer research
A new study published in European Urology Oncology has shed light on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). The researchers aimed to describe treatment trajectories and clinical outcomes in a large, multicenter real-world data (RWD) cohort under the PIONEER project. The study analyzed data from eight European
Prostate cancer
A new study published in European Urology Oncology has shed light on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). The researchers aimed to describe treatment trajectories and clinical outcomes in a large, multicenter real-world data (RWD) cohort under the PIONEER project. The study analyzed data from eight European
Prostate cancer
Researchers at AstraZeneca have made a groundbreaking discovery in the treatment of prostate cancer, revealing that a combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) can significantly improve outcomes for patients with metastatic, castration-resistant prostate cancer. This study, published in NAR Cancer, found that
Prostate cancer
Research conducted in Yogyakarta, Indonesia, by investigators from the Faculty of Medicine has shed light on the differences in pathological outcomes and safety between subcapsular orchiectomy and pharmacological androgen deprivation therapy (ADT) for prostate cancer management. A systematic search was conducted on various databases, and 13 studies meeting the inclusion
Cancer research
Research conducted at Capital Medical University has evaluated the quality, accuracy, and readability of prostate-cancer-related medical information produced by ChatGPT and DeepSeek. The study found that while both AI tools demonstrated potential for disseminating medical information, there may be variability in the quality and readability of the content generated. The
Cancer patients
A recent study has shed light on the efficacy and safety of magnetic resonance imaging-ultrasonography (MRI-US) fusion-guided focal cryoablation in treating localized prostate cancer. The research, published in BJU International, assessed the outcomes of 50 men with low- to intermediate-risk prostate cancer who underwent the procedure between December 2020 and
Cancer research
Researchers at Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Taiwan, have published a study evaluating the oncological outcomes of external beam radiation therapy (EBRT) versus high-intensity focused ultrasound (HIFU) in patients with stage II prostate cancer. The study retrospectively reviewed patients from the Chang Gung Research Database spanning
Cancer research
Researchers at AstraZeneca have made a groundbreaking discovery in the treatment of prostate cancer, revealing that a combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) can significantly improve outcomes for patients with metastatic, castration-resistant prostate cancer. This study, published in NAR Cancer, found that
Cancer research
Research conducted in Yogyakarta, Indonesia, by investigators from the Faculty of Medicine has shed light on the differences in pathological outcomes and safety between subcapsular orchiectomy and pharmacological androgen deprivation therapy (ADT) for prostate cancer management. A systematic search was conducted on various databases, and 13 studies meeting the inclusion
Cancer research
A major international trial, led by researchers from the University of College London (UCL), has found that a new combination of drugs significantly delays the progression of a life-threatening form of prostate cancer in men with specific genetic mutations. The Phase III AMPLITUDE trial tested the addition of niraparib, a
Prostate cancer
A free community talk focused on prostate health is set to take place in Exmouth, aiming to raise awareness and provide support for those affected by prostate-related conditions. The event, hosted at Raleigh Manor Care Home, will feature local prostate health support group leader Richard Watts, who will share his
Clinical trials
A newly developed radiopharmaceutical composition, created by inventors Jalomaki and Seppanen, has shown significant promise in treating prostate cancer with lower rates of toxicity. The composition, which targets prostate-specific membrane antigen (PSMA), has been designed to provide a safer and more effective treatment option for patients with metastatic castration-resistant prostate
